News
The US Food and Drug Administration (FDA) has granted accelerated approval for Regeneron Pharmaceuticals’ Lynozyfic ...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best Value Stocks to Buy According to Billionaires.
Adverum Biotechnologies, Inc. (NASDAQ:ADVM – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the five analysts that are covering the firm, MarketBeat reports. One analyst ...
This was the stock's third consecutive day of gains.
Regeneron Pharmaceuticals has won Food and Drug Administration accelerated approval of its Lynozyfic treatment for certain patients with the blood cancer multiple myeloma.
21h
InvestorsHub on MSNRegeneron Shares Climb Following FDA Approval of Blood Cancer TreatmentRegeneron Pharmaceuticals (NASDAQ:REGN) saw its stock increase by 2.8% after the U.S. Food and Drug Administration granted ...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt) to treat adult ...
Investing.com -- Regeneron Pharmaceuticals (NASDAQ: REGN) stock rose 2.8% after the U.S. Food and Drug Administration granted accelerated approval for the company’s blood cancer therapy Lynozyfic.
Allspring Global Investments Holdings LLC lessened its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report ...
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) was downgraded by stock analysts at Argus from a “buy” rating to a ...
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) shares hit a new 52-week high during mid-day trading on Monday after Wells Fargo & Company raised their price target on the stock from ...
Regeneron Pharmaceuticals REGN +2.83% Get Free Report has outperformed the market over the past 20 years by 13.87% on an annualized basis producing an average annual return of 22.35%. Currently, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results